FDA approval gutted: foreign regulators now decide US drug safety
S. 3081 — Reciprocity Ensures Streamlined Use of Lifesaving Treatments Act of 2025 · Filed by Ted Cruz (R-TX) · 1 cosponsor · Introduced Oct 30, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill creates a fast-track approval pathway for drugs, biologics, and medical devices that are already approved and marketed in certain foreign countries (those on the FDA's list of trusted regulators, plus the UK). If a product is lawfully sold abroad and meets basic safety criteria, the FDA can grant "reciprocal marketing approval" in the US within 30 days, bypassing the standard FDA review process. Congress can block the FDA's decision to deny approval via joint resolution.
Why we flagged it
The bill's operative mechanism is a streamlined approval pathway that substitutes foreign regulatory decisions for independent FDA review, directly benefiting pharmaceutical and medical device manufacturers seeking faster US market entry. The public-health framing ("lifesaving treatments") masks a structural shift in regulatory authority away from the FDA toward foreign agencies.
What the text implies
- The 30-day approval window is so compressed that meaningful FDA safety review becomes impossible; the agency is effectively rubber-stamping foreign decisions rather than conducting independent assessment.
- Congressional disapproval mechanism inverts the default: products are approved unless Congress votes to block them, placing burden on Congress to act rather than on sponsors to prove safety—a major shift in regulatory burden.
The full analysis lists 5 implications of this text.
Who stands to gain
pharmaceutical manufacturers; medical device makers; biologics companies